Betta Makes First U.S. Investment, Gains Oncology Asset
This article was originally published in PharmAsia News
Executive Summary
The targeted cancer therapeutics venture Xcovery has received a major investment from China's Betta Pharma as part of a licensing deal for a clinical stage oncology asset.